MammaPrint accurately identifies good prognosis group within clinically indeterminate risk patients.

Publication Name: Poster, ESMO 2008

Author(s): A. M. Glas , F. de Snoo, C. Dreezen, P. Roepman, R. Bender, L. Van ‘t Veer .

A 70-gene tumor expression profile was established as a powerful predictor of disease outcome in patients with breast cancer.(1,2) The test, known as “MammaPrint,” was validated in independent cohorts, and implementation was shown to be feasible in community hospitals.(3-7) We … Continued